Background: Adverse cardiovascular responses, such as increased blood pressure (BP) and pulse, have been a concern in developing obesity therapies. Abnormalities in BP circadian rhythm have been associated with increased cardiovascular events. Combined naltrexone/bupropion (NB) is a novel pharmacologic approach to obesity therapy. The effects of NB in obese subjects were examined in a 56-wk Phase 3 study. Wk 56 weight loss was -6.4% NB vs -1.2% Placebo (PBO) (P<0.001). NB-treated subjects had greater improvements in waist circumference, lipids, and hsCRP vs. PBO (P<0.05). In both groups, BP was essentially unchanged from baseline and greater reductions in BP were observed with greater weight loss. Results of an ambulatory BP monitoring (ABPM) substudy are reported here.
